VTRS$14.93
Chart
Performance
Key Stats
AI VTRS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldViatris Inc. presents a mixed investment profile. While it offers a substantial dividend yield and has a strong market presence in the pharmaceutical sector, it is experiencing declining revenues and a negative net income. Technical indicators are mixed, suggesting potential short-term volatility. Investors seeking income might find the dividend attractive, but growth prospects appear limited.
Thematic
Viatris operates within the stable but evolving pharmaceutical industry. Key themes include the increasing demand for generic and biosimilar drugs, as well as the growing importance of managing non-communicable diseases. However, the company faces challenges related to drug pricing pressures and intense competition.
Fundamental
Viatris shows a strong dividend yield and a manageable debt-to-equity ratio, indicating financial stability. However, declining revenues and persistent net losses in recent periods raise concerns about its earnings power and future growth. Free cash flow generation is positive but has also shown a downward trend.
Technical
The stock has experienced a significant decline over the past year, trading well below its 52-week high. While recent short-term performance shows some recovery, the longer-term trend is still bearish. Technical indicators like RSI and MACD suggest a mixed picture with potential for further downside or consolidation.
| Factor | Score |
|---|---|
| Healthcare Demand | 70 |
| Generic & Biosimilar Market Growth | 75 |
| R&D and Innovation | 50 |
| Regulatory Landscape | 60 |
| Competitive Intensity | 55 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Valuation | 0 |
| Profitability | 10 |
| Growth | 20 |
| Balance Sheet Health | 75 |
| Cash Flow | 60 |
| Dividends | 90 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 50 |
| Momentum | 55 |
| Moving Averages | 30 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Short-Term Performance
The stock has shown positive performance over the last 5 days (+5.06%) and 1 month (+2.52%).
Attractive Dividend Yield
The company offers a dividend yield of 5.12%, providing income to shareholders.
Bearish Points (10)
Significant Long-Term Underperformance
The stock has experienced considerable declines over the past 6 months (-15.91%), Year-to-Date (-22.68%), and 1 year (-18.94%), indicating persistent negative market sentiment.
Negative Earnings Per Share (EPS)
The EPS TTM is negative (-3.18), indicating the company is currently unprofitable on a per-share basis.
Calendar
May 2025
23
Ex-Dividend Date
June 2025
16
Next Dividend Date
August 2025
7
Next Earnings Date
H: $0.58
A: $0.56
L: $0.53
H: 3.55B
A: 3.46B
L: 3.40B
Profile
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Seasonals
Price Target
11.39 USD
The 39 analysts offering 1 year price forecasts for VTRS have a max estimate of 14.00 and a min estimate of 8.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Global leader in generic and specialty pharmaceuticals; direct competitor to Viatris across multiple therapeutic areas and markets.
Weight: 92
The spun-off generics and biosimilars arm of Novartis; a direct and significant global competitor to Viatris in both established generics and the growing biosimilar market.
Weight: 90
Spun off from Merck & Co., Organon focuses on women's health, biosimilars, and established brands, sharing a similar strategic approach to Viatris in managing mature product portfolios.
Weight: 88
A U.S.-based generic and specialty pharmaceutical company with a broad portfolio, making it a direct competitor to Viatris in several key markets.